GleamWall
中文EN

CDT CDT Equity Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1896212 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-70.5%
TTM EPS YoY199.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-49.2%
ROA-41.4%
ROIC (approx.)-37.1%
Asset turnover—

Leverage & solvency

Liabilities / assets14.1%
Debt / equity0.00x
Current ratio0.20x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.29x
Accruals ratio-29.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$5.05M$3.38M
SG&A expense$31.70M$12.04M
Operating income-$36.76M-$15.42M
Interest expense$200,000$32,000
Pretax income-$39.22M-$17.80M
Net income-$39.22M-$17.80M
EBITDA—-$15.41M
EPS (basic)-1,177.89-61,598.62
EPS (diluted)-1,177.89-61,598.62
Weighted avg. shares (diluted)33,300289
Balance sheet
Cash & equivalents$1.51M$554,000
Short-term investments—$600,000
Current assets$4.38M$2.71M
PP&E, net$269,000$40,000
Total assets$5.65M$4.19M
Current liabilities$12.82M$10.74M
Total liabilities$12.82M$10.99M
Shareholders' equity-$7.17M-$6.79M
Shares outstanding18461
Cash flow statement
Operating cash flow-$15.55M-$9.68M
Capital expenditure—$51,000
Free cash flow—-$9.73M
Investing cash flow-$808,000-$43,000
Financing cash flow$17.42M$6.07M
Depreciation & amortization—$10,000
Stock-based compensation$2.18M$1.63M
Share buybacks$106,000—

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.